Clinical and Experimental Vaccine Research

The Korean Vaccine Society (대한백신학회)
권호 표지
DOI QR코드

DOI QR Code

Adverse events following immunisation with the first dose of sputnik V among Iranian health care providers

  • Reza Jafarzadeh Esfehani (Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR)-Khorasan Razavi) ;
  • Masood Zahmatkesh (Mashhad Medical Council) ;
  • Reza Goldozian (Mashhad Medical Council) ;
  • Javad Farkhonde (Mashhad Medical Council) ;
  • Ehsan Jaripour (Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR)-Khorasan Razavi) ;
  • Asghar Hatami (Mashhad Medical Council) ;
  • Hamid Reza Bidkhori (Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR)-Khorasan Razavi) ;
  • Seyyed Khosro Shamsian (Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR)-Khorasan Razavi) ;
  • Seyyed AliAkbar Shamsian (Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR)-Khorasan Razavi) ;
  • Faezeh Mojahedi (Blood Borne Infections Research Center, Academic Center for Education, Culture and Research (ACECR)-Khorasan Razavi)
  • Received : 2021.11.07
  • Accepted : 2022.12.22
  • Published : 2023.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Since late 2019, the novel coronavirus disease has been a global concern, and alongside preventive strategies, including social distancing and personal hygiene, vaccination is now the primary hope for controlling the pandemic. Sputnik V is an adenovirus vector vaccine used against coronavirus disease 2019 (COVID-19) among Iranian health care providers, and there is a lack of information regarding the Adverse Events Following Immunisation (AEFI) by Sputnik V among the Iranian population. The present study aimed to evaluate AEFI by Sputnik V vaccine among Iranian population. Materials and Methods: Every member of the Islamic Republic of Iran Medical Council received their first dose of the Sputnik V vaccine in Mashhad (Iran) and was referred to receive their second dose enrolled in the present study and asked to fill an English language checklist asking about development of any AEFI following immunization with the first dose of Sputnik V vaccine. Results: A total number of 1,347 with a mean±standard deviation age of 56.2±9.6 years filled the checklist. Most of the participants were male (838 [62.2%]). The present study demonstrated that immunization with the first dose of Sputnik V results in at least one AEFI in 32.8% of the Iranian medical council members. Most of the AEFI was related to musculoskeletal symptoms, including myalgia. By considering the age of 55 years as a cut-off point, individuals younger than 55 had a higher rate of AEFI (41.3% vs. 22.5%, p=0.0001). Male gender, use of analgesics, beta-blockers, and previous COVID-19 infection have a lower chance of developing AEFI (p<0.05). Conclusion: The present study demonstrated that most of the AEFI was related to musculoskeletal symptoms, including myalgia, and older individuals, male gender and those receiving analgesics and beta-blockers were less likely to develop AEFI following immunization with the first dose of Sputnik V.

Keywords

References

  1. Forni G, Mantovani A; COVID-19 Commission of Accademia Nazionale dei Lincei, Rome. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ 2021;28:626-39.
  2. Pormohammad A, Zarei M, Ghorbani S, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines (Basel) 2021;9:467.
  3. Rogliani P, Chetta A, Cazzola M, Calzetta L. SARS-CoV-2 neutralizing antibodies: a network meta-analysis across vaccines. Vaccines (Basel) 2021;9:227.
  4. Bucci EM, Berkhof J, Gillibert A, et al. Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial. Lancet 2021;397:1881-3.
  5. Rzymski P, Zeyland J, Poniedzialek B, Malecka I, Wysocki J. The perception and attitudes toward COVID-19 vaccines: a cross-sectional study in Poland. Vaccines (Basel) 2021;9:382.
  6. Mallapaty S. Iran hopes to defeat COVID with homegrown crop of vaccines. Nature 2021;596:475.
  7. Shamabadi A, Akhondzadeh S. Significant reduction in hospitalization due to COVID-19 as a medium-term outcome following coronavirus vaccination in Iran. J Iran Med Counc 2021;4:113-4.
  8. Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet 2020;396:887-97.
  9. Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021;397:671-81.
  10. Lawton G. Sputnik V vaccine goes global. New Sci 2021;250:10-1.
  11. Dawood AA. The effects of the Russian vaccine (Sputnik V) on the volunteers. Apollo Med 2021;18:52-3.
  12. Pagotto V, Ferloni A, Mercedes Soriano M, et al. Active monitoring of early safety of Sputnik V vaccine in Buenos Aires, Argentina. Medicina (B Aires) 2021;81:408-14.
  13. Montalti M, Solda G, Di Valerio Z, et al. ROCCA observational study: early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance. EClinicalMedicine 2021;38:101027.
  14. Cazzola M, Matera MG. Review 2: "Qualitatively distinct modes of Sputnik V vaccine-neutralization escape by SARSCoV-2 Spike variants". Rapid Rev Infect Dis [Preprint] 2021 May 29. https://doi.org/10.1162/2e3983f5.3202126f
  15. Ikegame S, Siddiquey MN, Hung CT, et al. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nat Commun 2021;12:4598.